(5S)-5-<2'-(t-butyldimethylsilyloxy)-ethyl>-2,2-dimethyl-<1,3>dioxolan-4-one | 172958-90-6

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: (5S)-5-<2'-(t-butyldimethylsilyloxy)-ethyl>-2,2-dimethyl-<1,3>dioxolan-4-one
• 英文别名: (S)-5-[2-(tert-butyl-dimethyl-silanyloxy)-ethyl]-2,2-dimethyl-[1,3]dioxolan-4-one；(5S)-5-[2-[tert-butyl(dimethyl)silyl]oxyethyl]-2,2-dimethyl-1,3-dioxolan-4-one
• CAS: 172958-90-6
• 化学式: C₁₃H₂₆O₄Si
• 分子量: 274.433
• InChiKey: WALPPAFJTQZXHD-JTQLQIEISA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.08
• 重原子数：
  18
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.92
• 拓扑面积：
  44.8
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (5S)-5-<2'-(t-butyldimethylsilyloxy)-ethyl>-2,2-dimethyl-<1,3>dioxolan-4-one 在 4-甲基苯磺酸吡啶 作用下， 以 乙醚 、 二氯甲烷 为溶剂， 反应 1.5h， 生成 tert-butyl-dimethyl-[2-((S)-2,2,5,5-tetramethyl-[1,3]dioxolan-4-yl)-ethoxy]-silane
  参考文献：
  名称：

  Saponaceolides: Differential cytotoxicity and enantioselective synthesis of the right-hand lactone moiety

  摘要：

  The enantioselective synthesis of the right-hand lactone moiety 5 of saponaceolide B, 2, is described. The mean graph profiles of 5 do not match the characteristic patterns of differential cytotoxicity of saponaceolides A, 1, and B, 2, in the NCI human disease-oriented tumor screening panel, pointing out the need of the entire saponaceolide structure for maintaining the specificity and potency of the antitumor activity. En route to 5 several useful chiral building blocks, such as compounds 6, 10, 19, 27, and 28 were prepared.

  DOI：

  10.1016/0957-4166(95)00371-1
• 作为产物：
  描述：

  (S)-[2,2-二甲基-5-氧代二氧戊环-4-基]乙酸 在 咪唑 、 4-二甲氨基吡啶 、 dimethyl sulfide borane 作用下， 以 四氢呋喃 、 N,N-二甲基甲酰胺 为溶剂， 反应 27.0h， 生成 (5S)-5-<2'-(t-butyldimethylsilyloxy)-ethyl>-2,2-dimethyl-<1,3>dioxolan-4-one
  参考文献：
  名称：

  Saponaceolides: Differential cytotoxicity and enantioselective synthesis of the right-hand lactone moiety

  摘要：

  The enantioselective synthesis of the right-hand lactone moiety 5 of saponaceolide B, 2, is described. The mean graph profiles of 5 do not match the characteristic patterns of differential cytotoxicity of saponaceolides A, 1, and B, 2, in the NCI human disease-oriented tumor screening panel, pointing out the need of the entire saponaceolide structure for maintaining the specificity and potency of the antitumor activity. En route to 5 several useful chiral building blocks, such as compounds 6, 10, 19, 27, and 28 were prepared.

  DOI：

  10.1016/0957-4166(95)00371-1

文献信息

• Substituted Pyrrolidine-2-Carboxamides
  申请人：Bartkovitz David Joseph

  公开号：US20100152190A1

  公开（公告）日：2010-06-17

  There are provided compounds of the formula wherein X, Y, R 1 , R 2 , R 3 , R 3 , R 4 , R 5 , R 6 and R 7 are as described herein and enantiomers and pharmaceutically acceptable salts and esters thereof. The compounds are useful as anticancer agents.

  提供了以下式子的化合物，其中X，Y，R1，R2，R3，R4，R5，R6和R7如此描述，其对映体和药学上可接受的盐和酯。这些化合物可用作抗癌剂。
• Substituted pyrrolidine-2-carboxamides
  申请人：Bartkovitz David Joseph

  公开号：US08354444B2

  公开（公告）日：2013-01-15

  There are provided compounds of the formula wherein X, Y, R1, R2, R3, R3, R4, R5, R6 and R7 are as described herein and enantiomers and pharmaceutically acceptable salts and esters thereof. The compounds are useful as anticancer agents.

  提供了以下式子的化合物：其中X，Y，R1，R2，R3，R3，R4，R5，R6和R7的描述如下，并提供其对映异构体和药学上可接受的盐和酯。这些化合物可用作抗癌剂。
• Saponaceolides: Differential cytotoxicity and enantioselective synthesis of the right-hand lactone moiety
  作者：Giovanni Vidari、Gianluigi Lanfranchi、Patrizia Sartori、Stefano Serra

  DOI：10.1016/0957-4166(95)00371-1

  日期：1995.12

  The enantioselective synthesis of the right-hand lactone moiety 5 of saponaceolide B, 2, is described. The mean graph profiles of 5 do not match the characteristic patterns of differential cytotoxicity of saponaceolides A, 1, and B, 2, in the NCI human disease-oriented tumor screening panel, pointing out the need of the entire saponaceolide structure for maintaining the specificity and potency of the antitumor activity. En route to 5 several useful chiral building blocks, such as compounds 6, 10, 19, 27, and 28 were prepared.